Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

The FDA has granted Breakthrough Therapy Designation to Bristol Myers Squibb (BMY) and SystImmune’s experimental drug iza-bren for treating advanced EGFR-mutant lung cancer after prior therapies fail, ...

Friday, August 15, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily ...

Bristol-Myers Squibb’s second quarter saw flat overall sales, but the company surpassed Wall Street expectations for both ...

Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks. Read why BMY stock is a buy.

The 31st One Mind Music Festival on September 13, 2025 will be hosted at Staglin Family Vineyard in Rutherford, CA. The ...

Bristol Myers Squibb (NYSE: BMY) is a big name in healthcare. And over the years, it has always found ways to grow and expand its business. But this hasn't been a good buy of late. It's not just ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top stocks sold by hedge funds. On July 28, Bristol Myers, in ...

We expect Bristol Myers Squibb’s earnings to plunge to $0.76 in per share in 2024, versus $7.51 last year. However, this figure is expected to rebound to $7.30 in 2025.

Bristol Myers Squibb stock tanked in April after management lowered the midpoint of its earnings outlook for 2024 from $7.25 per share to just $0.55 to account for a $12.1 billion IPRD charge ...